title: Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
abstract: The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with ⩾2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (⩾2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.
authors: University of Nantes, Nantes, France.
authors: P
authors: P
authors: Moreau
authors: Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
authors: D
authors: D
authors: Joshua
authors: National University Cancer Institute, National University Health System; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
authors: W-J
authors: WJ
authors: Chng
authors: University of Torino, Torino, Italy.
authors: A
authors: A
authors: Palumbo
authors: Heidelberg Medical University, Heidelberg, Germany.
authors: H
authors: H
authors: Goldschmidt
authors: University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
authors: R
authors: R
authors: Hájek
authors: CHRU Lille Hôpital Claude Huriez, Lille, France.
authors: T
authors: T
authors: Facon
authors: Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
authors: H
authors: H
authors: Ludwig
authors: University Hospital Brno, Brno, Czech Republic.
authors: L
authors: L
authors: Pour
authors: Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
authors: R
authors: R
authors: Niesvizky
authors: Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
authors: A
authors: A
authors: Oriol
authors: Hospital Clínic de Barcelona, Barcelona, Spain.
authors: L
authors: L
authors: Rosiñol
authors: Hematological Department, First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia.
authors: A
authors: A
authors: Suvorov
authors: Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
authors: G
authors: G
authors: Gaidano
authors: Department of Hematooncology, University Hospital Olomouc, Olomouc, Czech Republic.
authors: T
authors: T
authors: Pika
authors: Universitätsklinikum Tübingen, Tübingen, Germany.
authors: K
authors: K
authors: Weisel
authors: University Multiprofile Hospital for Active Treatment 'Sv. Georgi' and Medical University, Plovdiv, Bulgaria.
authors: V
authors: V
authors: Goranova-Marinova
authors: Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
authors: H H
authors: HH
authors: Gillenwater
authors: Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
authors: N
authors: N
authors: Mohamed
authors: Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
authors: S
authors: S
authors: Aggarwal
authors: Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
authors: S
authors: S
authors: Feng
authors: National and Kapodistrian University of Athens, Athens, Greece.
authors: M A
authors: MA
authors: Dimopoulos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069286:Bortezomib / Q000008:administration & dosage* / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D018572:Disease-Free Survival; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D009842:Oligopeptides / Q000008:administration & dosage* / Q000627:therapeutic use; D012008:Recurrence; D016879:Salvage Therapy / Q000379:methods* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D009842:Oligopeptides; D000069286:Bortezomib; C524865:carfilzomib; D003907:Dexamethasone